Executive summary
Medical radioisotopes are unlike most commodities. Their value decays continuously from the moment of production. For countries dependent on imports, this decay is not theoretical. It is a measurable, recurring loss that directly affects healthcare outcomes, costs, and reliability.
India currently imports a significant fraction of its critical medical isotopes. In doing so, it pays an invisible but substantial “decay tax” that cannot be eliminated through better logistics alone.
1. Radioisotopes are perishable by physics
Unlike pharmaceuticals whose shelf life is governed by chemistry, radioisotopes decay according to immutable nuclear laws. Each isotope has a fixed half-life that determines how rapidly usable activity diminishes over time.
This decay is:
- Continuous
- Predictable
- Unavoidable
No packaging, cold chain, or insurance product can halt it.
2. The supply chain is longer than the half-life
For imported isotopes, the time between production and patient use typically includes:
- Reactor or accelerator production scheduling
- Processing and quality assurance
- International transport
- Customs clearance
- Domestic logistics
- Radiopharmacy preparation
Even under ideal conditions, this introduces delays that are comparable to, or longer than, the half-lives of several clinically important isotopes.
The result: by the time the isotope reaches the patient, a significant fraction of its original activity is already gone.
3. Activity loss is not linear — it is compounding
Radioactive decay is exponential. This means:
- Early delays cause disproportionate losses
- Marginal improvements in logistics yield diminishing returns
- Centralised production magnifies vulnerability
For short- and medium-lived isotopes, even a 24–72 hour delay can translate into double-digit percentage losses in usable activity.
This loss must be compensated by:
- Ordering higher initial activity
- Paying higher prices
- Accepting lower imaging or therapeutic quality
- Or, in some cases, cancelling procedures altogether
4. Who ultimately pays the decay tax?
The decay tax is distributed across the system:
- Hospitals face scheduling uncertainty
- Patients experience delays or reduced quality
- Payers absorb higher per-procedure costs
- The national health system bears systemic inefficiency
This tax is paid every week, not just during global supply disruptions.
5. Why logistics alone cannot solve this
Improving transport speed helps, but only marginally. The fundamental constraint is geography combined with half-life physics.
As long as production is geographically distant from end use, decay losses remain structurally embedded in the system.
This is why isotope supply is not merely a trade issue. It is an infrastructure question.
The fragility is documented. The OECD-NEA’s 2025 review of medical-radioisotope supply notes that the global Mo-99 production base depends on a handful of ageing research reactors, five of which are more than fifty years old. In 2024, two concurrent reactor shutdowns reduced global Mo-99 supply by approximately 40 per cent. For an importing country, every such event is paid in patient delays and degraded imaging quality, downstream of decisions taken thousands of kilometres away.
6. Reframing the problem
The key insight:
Medical isotopes are not scarce because they are hard to make. They are scarce because they are hard to move fast enough.
Any long-term solution must therefore shorten the distance between production and use.
Closing note
Reducing India’s decay tax is not about self-sufficiency for its own sake. It is about aligning healthcare delivery with the physical realities of radioactive decay.
This requires a shift from centralised, import-dependent models to distributed, domestically anchored production capabilities.
The rest is engineering.